Three New Treatment Surveys!

We need your help!

Myeloma Canada is seeking input from people impacted by multiple myeloma regarding four new treatments/treatment combinations soon undergoing reimbursement review at Canada’s Drug Agency (CDA) and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS).

These three surveys are intended for patients who have already received the treatment(s) under review and their caregivers, and/or patients who would be eligible for these treatments based on their indication and their caregivers.

Surveys

Anitocabtagene autoleucel - BCMA-targeted CAR T-cell therapy

For patients with relapsed/refractory multiple myeloma who have received at least 3 prior lines of therapy; including a proteasome inhibitor (PI) an immunomodulatory agent (IMiD); and an anti-CD38 monoclonal antibody.

Teclistamab – BCMA-targeted bispecific antibody

For patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy, including lenalidomide and an anti-CD38 monoclonal antibody.

Talquetamab – GPRC5D targeted bispecific antibody - in combination with daratumumab and pomalidomide (Tal-DP) OR in combination with daratumumab (Tal-D)

For patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy, including lenalidomide, a proteasome inhibitor, and with no prior exposure to an anti-CD38 monoclonal antibody.

Where to begin

Especially if you have NOT received any of the treatments under review, we recommend you start with the survey on anitocabtagene autoleucel, which is open to all patients and caregivers.

At the end of this survey, you will be able to continue on to the other surveys you are eligible for.

Start here!

Please complete the surveys by November 17, 2026 (11:59 PM EST).

Questions? Contact contact@myeloma.ca and include “Treatment Surveys” in the subject line.

Thank you in advance for participating!

Myeloma Canada's mission: To improve the lives of all Canadians affected by myeloma by accelerating access to the best care while advancing research toward its cure and prevention.

Si vous préférez recevoir ces informations en français, écrivez-nous à contact@myelome.ca.

To donate to Myeloma Canada

please visit myeloma.ca or call us toll-free at 1-888-798-5771.

Donate here

Myeloma Canada charitable number: 862533296RR0001